Report: Sanofi has billion-dollar dengue opportunity in India

Sanofi Pasteur's India head Stephan Barth

Analysts have said Sanofi's ($SNY) dengue vaccine, once approved, could rake in €1 billion, or $1.31 billion, a year. But as the Business Standard reports, India alone is a billion-dollar opportunity. According to a report from Brandeis University, the number of cases in the country is almost 300 times higher than government figures. "Over recent months, we have seen a worrying increase in cases, putting a huge strain on health care systems," Stephan Barth, Sanofi Pasteur's India head, told the paper, noting that India is part of the company's global development strategy for the dengue vaccine. Story | Report

Virtual Clinical Trials Summit

Virtual Clinical Trials Summit: The Premier Educational Event Focused on Decentralized Clinical Trials

In this virtual environment, we will look at current and future trends for ongoing virtual trials, diving into the many ways companies can improve patient engagement and trial behavior to enhance retention with a focus on emerging technology and harmonized data access across the clinical trial system.